B7‐H3 drives immunosuppression and Co‐targeting with CD47 is a new therapeutic strategy in β‐catenin activated melanomas
Pigment Cell & Melanoma Research · 2023
DOI: 10.1111/pcmr.13091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2023. Verfasst von Min Hsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NCI NIH HHS, NIH HHS, Melanoma Research Alliance.
Abstract (Originalsprache)
In melanoma, immune cell infiltration into the tumor is associated with better patient outcomes and response to immunotherapy. T‐cell non‐inflamed tumors (cold tumors) are associated with tumor cell‐intrinsic Wnt/β‐catenin activation, and are typically resistant to anti‐PD‐1 alone or in combination with anti‐CTLA‐4 therapy. Reversal of the ‘cold tumor’ phenotype and identifying new effective immunotherapies are challenges. We sought to investigate the role of a newer immunotherapy agent, B7‐H3, in this setting. RNA sequencing was used to identify co‐targeting strategies upon B7‐H3 inhibition in a well‐defined preclinical melanoma model driven by β‐catenin. We found that immune checkpoint molecule B7‐H3 confers a suppressive tumor microenvironment by modulating antiviral signals and innate immunity. B7‐H3 inhibition led to an inflamed microenvironment, up‐regulation of CD47/SIRPa signaling, and together with blockade of the macrophage checkpoint CD47 resulted in additive antitumor responses. We found that the antitumor effects of the B7‐H3/CD47 antibody combination were dependent on cytokine signaling pathways (CCR5/CCL5 and IL4).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Pathology, The University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- Melanoma Research Alliance
- National Institutes of Health
Zitieren
APA
Hsu, M., Martin, T. C., Vyas, N. S., Desman, G., Mendelson, K., Horst, B., Parsons, R. E., & Celebi, J. T. (2023). B7‐H3 drives immunosuppression and Co‐targeting with CD47 is a new therapeutic strategy in β‐catenin activated melanomas. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.13091
Vancouver
Hsu M, Martin TC, Vyas NS, Desman G, Mendelson K, Horst B, et al. B7‐H3 drives immunosuppression and Co‐targeting with CD47 is a new therapeutic strategy in β‐catenin activated melanomas. Pigment Cell & Melanoma Research. 2023. doi:10.1111/pcmr.13091
BibTeX
@article{Hsu2023,
author = {Hsu, Min and Martin, Tiphaine C and Vyas, Nikki S and Desman, Garrett and Mendelson, Karen and Horst, Basil and Parsons, Ramon E and Celebi, Julide Tok},
title = {B7‐H3 drives immunosuppression and Co‐targeting with CD47 is a new therapeutic strategy in β‐catenin activated melanomas},
journal = {Pigment Cell & Melanoma Research},
year = {2023},
doi = {10.1111/pcmr.13091}
}
EUVIMED